Recently 15-p-iodophenyl-//-methyl-pentadecanoic acid (BMPPA) was proposed for use in myocardial scintigraphy, as a possible probe of metabolic processes other than//-oxidation. In 19 patients (CAD/I 5, St.p. Mi/7; control 4) myocardial scintigraphy was carried out after i.v. 1-123-BMPPA (~4 mCi). Data were collected (LAO 45°/14; anterior/5).for 100 rain in the fasted patients. Organ to background (BG) ratios were calculated for the heart (H) and liver (L), and the elimination (E) behaviour was analyzed from BG (vena cava region) corrected time activity curves. In 10 patients plasma and urine were examined. By CHCla/MeOH extraction of plasma samples (90 rain after injection), both in water and in organic medium soluble catabolites were found. TLC fractionation showed that those were co-migrating, compared to standards, with bencoic acid, BMPPA and trigylcerides. In the urine (0-2 h after injection, 4.1% dose) hippuric acid was found. The mean t-max of BMPPA occurred at 15 rain in the heart and at 9 rain in the liver (P<0.01), with H/BG and L/BG ratios of 1.8 and 2.1, respectively. The elimination of BMPPA was slower from the heart than from the liver (P<0.01). It was biexponential from the liver in all cases (2:t/2 I, ll.4min; t/2 II, 92min; t/2 I uncor., 38 min) with the size of phase I smaller than that of phase II (~: I/II, 0.57). From the heart BMPPA turnover was biexponential in 11 patients (if: t/2 I, 13.8 min; t/2 II, 187 min; t/2 I uncor., 65 rain; I/II, 0.34), but monoexponential in 8 02: t/2, 218 rain).
In 13 diseased regions (MI/7) BMPPA uptake was reduced, and the E behaviour was mostly abnormal as compared to the respective undiseased region. We conclude that BMPPA is a useful agent for myocardial scintigraphy. Its longer retention time in the heart compared to unbranched radioiodinated fatty acids may facilitate SPECT studies. E behaviour and plasma analysis indicate that BMPPA is metabolically broken down. Yet, the complexity of the supposed mechanism may impede curve interpretation in terms of specific metabolic pathways.
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Several radioiodinated fatty acid analogues have been developed for myocardial scintigraphy (Poe et al. 1976 ; MaOffprint requests to: R. Dudczak, M.D. (address see above) chulla et al. 1978 Knapp et al. 1981) . In clinical studies with radioiodinated aliphatic and aromatic fatty acids, the uptake pattern and the myocardial release rate of these compounds were evaluated and believed to give some hint on myocardial fatty acid metabolism (Freundlieb et al. 1980; van der Wall et al. 1981 a, b; Feinendegen et al. 1981 ; Dudczak et al. 1983 ). Yet, while there is evidence that these compounds may serve as metabolic substrates, being subsequently utilized by the myocardium in a comparable manner to natural fatty acids (Dudczak et al. 1984; Reske et al. 1984) , there is controversy concerning the interpretation of myocardial turnover rates in terms of specific metabolic pathways (Feinendegen et al. 1981 ; Reske et al. 1984; Kloster et al. 1984; Coenen et al. 1981; Visser et al. 1985) . In addition the generation of free iodide in studies with an omega-iodo branched chain alkyl fatty acid seemed to indicate the occurrence of chemical or enzymatic deiodination, since it was thought that in the//-position, methylated fatty acids are not prone to metabolic cleavage (Livni et al. 1982; Otto etal. 1984) . However, species-specific differences might exist, since the behaviour of this compound appeared different in rats and dogs (Livni et al. 1982) . Also, iodine binding to aliphatic compounds is rather unstable, which might facilitate unspecific deiodination of such fatty acids; in contrast, iodine binds strongly to an aromatic molecule.
Recently, 15-p-iodophenyl-fl-methyl-pentadecanoic acid (BMPPA) was proposed for use in myocardial scintigraphy, as it is a compound in which unspecific deiodination is unlikely to occur (Goodman et al. 1984) . According to previous suggestions this compound, being methylated in the //-position, should serve as an indicator of metabolic processes other than//-oxidation (Livni et al. 1982; Otto et al. 1984) . In rat experiments BMPPA exhibited a high myocardial uptake. In addition the modification in its molecular structure resulted in a prolonged myocardial residence time. In heart extracts radioactivity was mainly found in the triglyceride and phospholipid fractions. In further studies in hypertensive rats a disparity was seen in the uptake pattern of a perfusion tracer (normal) and this compound (abnormal) (Yonekura et al. 1985) . These animal experiments support the clinical application of BMPPA for myocardial scintigraphy.
The aim of the present study was to evaluate the clinical feasibility of BMPPA for myocardial scintigraphy in man. We further attempted to evaluate whether BMPPA is metabolically degraded by human tissue.
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Patients and Methods
Nineteen patients (controls, n = 4; coronary artery disease, n = 15, St.p. Mi, n = 7) who underwent coronary angiography because of chest pain were studied. Myocardial scintigraphy with BMPPA was carried out in the fasted patients using either a LFOV gamma-camera (n = 4) or a mobile gamma-camera (n = 15), having the collimator in the LAO 45 ° (n= 14) or in the anterior projection (n= 5). After i.v. injection of 2-5 mCi 123I-BMPPA data were accumulated in a 64× 64 word matrix for 100 rain with a frame rate of l/rain.
Besides visual interpretation of scintigrams, background (vena cava region) corrected time activity curves of the heart (global and regional) and liver were analyzed, which were fitted as appropriate with either a biexponential or a monoexponential function. Parameters evaluated were: activity peak time (t-max), target to background ratios, and the elimination half-time of the initial (t/2 I) and second (t/2 II) phase (in min). In addition the contribution of each phase on the elimination curve was calculated by a component ratio (counts phase I/counts phase II at t-max).
In addition to scintigraphy 123I radioactivity was analyzed in plasma (5 rain and 90 min after injection) and urine (0-2 h after injection) samples for the occurrence of a23I BMPPA metabolites or degradation products. Untreated and acidified (HC1, pH ~-2) samples (0.5 ml) were extracted with chloroform/methanol (2 : 1 v/v, 2.5 ml) and the phases separated by centrifugation, a 23I radioactivity in the respective phases (organic, aqueous, solid) was counted in a well scintillation counter. The organic phase was concentrated by a stream of nitrogen in a water bath and subsequently dissolved in chloroform/methanol. Thereafter its radioactivity distribution was assayed by thin layer chromatography (TLC) using silica gel plates and chloroform/acetic acid (9:1 v/v) as eluent.
Results
Following a rapid decrease in 123I radioactivity in blood, with the lowest values between 15-20 min after tracer administration, there was a slight increase in 123I blood activity. Due to BMPPA degradation both in water and in organic medium, soluble catabolites were found in plasma samples. Initially most of the activity was extracted into the organic phase (5min after injection: 76.7_+3.9%), thereafter decreasing (90 rain: 32.2___ 8.7%), while activity in the aqueous phase increased (5rain after injection: 3.6_+1.9%; 90min after injection: 40.3_+8.1%). Activity in the aqueous phase resembled weak acids in its behaviour since in acidified samples most of the activity was extracted into the organic phase (Table 1) . By TLC fractionation two to three activity peaks were seen, which wer e corn±grating as compared to standards with BMPPA, triolein and bencoic acid (Table 2) .
Urinary excretion was somewhat lower as compared to previous findings with the unmethylated compound (excretion % dose: 0-2 h after injection, 4.1 +0.9%; 2-16 h after injection, 10.5 -+ 2.2%). In urine analyzed by TLC, an activity peak was found comigrating with the omega-iodo-hippuric acid standard, indicating BMPPA degradation.
As the total extraction of BMPPA in the liver exceeds that the heart, BMPPA degradation products formed in the liver will contribute most of the ~ 23I radioactivity found Table 3 . Distribution of lzaI-BMPPA in heart and liver in 19 patients (2± SD) Heart Liver t-max (min) 14.9 ± 3.40 8.80 ± 2.30 Target/BG ratio at t-max 1.8 + 0.30 2.05 ± 0.30 Target/BG ratio at t-100 min t .6 _ 0.30 1.45 _ 0.26 in plasma samples. However, besides the main source of BMPPA catabolism, these findings hint toward the metabolic usage and degradation of la3I-BMPPA by human tissue. Scintigraphic findings appeared comparable to previous findings using unbranched radioiodinated fatty acid analogues in myocardial scintigraphy. However, in contrast to the latter, scintifotos of sufficient quality could be obtained up to 90-120 min after tracer injection. The regional myocardial uptake of 123I-BMPPA was reduced in infarcted 62.4 +20.7 69.6 +22.0 C-I/C-II Ratio 0.36+ 0.15 0.28-t-0.14" "" chronic" ischemic (N = 6) ; b Infarcted region (N-= 5) * P<0.01 Significantly different compared to the respective normal region regions (6/7), but also in non-infarcted regions supplied by stenosed vessels (7/25). Surprisingly, the metabolic usage of BMPPA appeared different for heart and liver, as indicated by the respective time activity curves. BMPPA uptake and elimination was higher and faster, respectively, from the liver than from the heart (Table 3 ). The time activity curve from the liver fitted a biexponential function, whereas that from the heart was monoexponential in 8 patients but biexponential in the remaining 11 patients (Table 4) .
The regional myocardial turnover was abnormal from all diseased regions (from those with a reduced as well as from those with a normal regional BMPPA uptake) showing a prolonged initial elimination half-time and/or a reduced component ratio (Table 5 ).
Conclusion
Our data show that 12aI-BMPPA can be used for myocardial scintigraphy in man. Its longer myocardial retention $47 as compared to unmethylated radioiodinated fatty acid analogues may facilitate SPECT studies. This 3-methyl branched chain fatty acid is prone to metabolic usage and degradation, an item not discussed previously. The steps theoretically required for its degradation are more complex than those involved in the degradation of unbranched fatty adds.
Several pathways for the oxidative degradation of 123I BMPPA by human tissue appear possible. It may involve ATP-dependent carboxylation of the methyl group (catalyzed by biotin), then followed by acetic acid cleavage. The resulting 15-pIPPA-CoA may then undergo fl-oxidation, finally forming hippuric acid by condensation of bencoic acid with glycine. As another possibility it may include e-oxidation, followed by propionyl-CoA cleavage of the subsequently activated compound, then fl-oxidation of the resulting even-numbered phenylated compound may proceed, finally producing phenylaceturic acid formed by the condensation of phenylacetic acid and glycine (Mahler and Cordes 1968) .
The above mentioned complexity of BMPPA metabolism may favour the use of BMPPA as compared to other radioiodinated straight chain fatty acid analogues. Possibly it makes it more sensitive to recognize patients with heart disease; however, the interpretation of the myocardial time activity curve is limited in terms of specific metabolic pathways.
